Modulation of Adhesion Molecules in Patients with AML During Immunotherapy with IL-2
Cell-to-cell interactions in the immune system are mediated by several different families of receptors on the cell surface, known as adhesion molecules. These adhesion molecules influence many diverse processes including growth, differentiation, migration, and killer-target cell interactions. To fulfill these effects, the density and the expression of these glycoproteins varies in relation to the cellular state of activation. The expression of these adhesion molecules is shown to be modulated by interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin (IL) 1,4, and 7 [1–3]. IL-2 has been shown to induce an upregulation of some adhesion molecules in vitro . However, it remains unclarified, whether this modulation is mediated by IL-2 itself or by release of secondary cytokines. Additional, no data are available so far concerning the modulation of adhesion molecules after immunotherapy with IL-2. In this study we focussed our interest on the expression of adhesion molecules on peripheral blood lymphocytes (PBL) and the serum levels of soluble CD54 (ICAM-1) in vivo after immunotherapy with IL-2.
KeywordsMigration Leukemia Interferon Integrin FITC
Unable to display preview. Download preview PDF.
- 2.Stotter H, Custer MC, Bolton ES, Guedez L, Lotze MT (1991) IL-7 induces human lymphokineactivated killer cell activity and is regulated by IL-4. J Immunology 146 (1): 150–155Google Scholar
- 8.Foa R, Meloni G, Tosti S, Fierro MT, Gavosto F, Mandelli F (1989) Recombinant IL2 in the treatment of acute leukemia: a pilot study. Blood 74: 357aGoogle Scholar
- 9.Bergmann L, Mitrou PS, Hoelzer D (1992) Interleukin-2 in the treatment of acute myelocytic leukemias: in vitro data and presentation of a clinical concept. In: Haematology and Blood Transfusion 34, Hiddemann et al. (Eds.), Springer Verlag, Berlin, 601–607Google Scholar
- 10.Fenchel K, Bergmann L, Martin H, Jahn B, Mitrou PS, Hoelzer D (1991) Clinical and biological effects of Interleukin-2 as late consolidation therapy in 2nd remission of acute myelocytic leukemia with and without autologous bone marrow transplantation. Haematologica Vol. 76(4): 55Google Scholar
- 12.Geissler D, Gaggl S, Most J, Greil R, Herold M, Dietrich M (1990) A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor alpha, interferon gamma, and interIeukin-1. Eur J Immunol 20(12): 2591–2596PubMedCrossRefGoogle Scholar
- 13.Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS (1991) Cytokine release in cancer patients treated with interleukin-2. J Immunotherapy (in press)Google Scholar